The outcome of Pluristem Therapeutics Inc. (NASDAQ: PSTI)’s PLX-PAD in a trial treatment of Duchenne muscular dystrophy has been revealed and it is a positive one. That paves the way for continued study and possible development of the compound to tackle Duchenne. It was the Association Duchenne Israel (ADI) that approached Pluristem to request that they be allowed to test PLX-PAD as a potential treatment for Duchenne and the company agreed to the request.
As such, the preclinical trial of PLX-PAD in mouse with Duchenne was carried out in conjunction with ADI. Members of ADI are parents with children afflicted by Duchenne. As such, they have demonstrated remarkable commitment to find a cure for Duchenne so that they can give hope to their suffering children and possibly millions of others in the world.
It is estimated that Duchenne affects about one in every 3,500 boys. The neuromuscular disorder can lead to severe disability and death. It worries many parents because there is currently no cure for it. Perhaps that further explains why ADI is showing unrelenting commitment to see if Pluristem Therapeutics Inc. (NASDAQ:PSTI)’s PLX-PAD can cure the condition. ADI is showing its support for PLX-PAD through a combination of research, clinical trials of the compound and advocacy.
Positive Phase 2 results
ADI approached Pluristem Therapeutics to test PLX-PAD for Duchenne after the compound showed remarkable success in the treatment of muscle injury in a Phase 2 clinical trial. As such, Pluristem donated PLX-PAD to the group to help them study its efficacy in Duchenne treatment. A company called Science in Action backed the program of testing PLX-PAD in Duchenne.
Mouse model Pluristem Therapeutics Inc. (NASDAQ: PSTI)
In a mouse model, Pluristem Therapeutics Inc. (NASDAQ:PSTI)’s PLX-PAD was able to reduce a marker of muscle injury called CPK by about 50% when compared with a placebo. With that, it became apparent that PLX-PAD could become a breakthrough therapy in managing the symptoms of Duchenne.
As such, the findings have triggered increased desire among ADI members to continue studying PLX-PAD. That is because the group believes that new therapeutic approaches are needed to combat Duchenne and PLX-PAD offers that unique approach.